Efficacy of cell-based immunotherapies on patients with glioma: an umbrella review of systematic reviews and meta-analysis protocol

IntroductionGlial brain tumours are highly mortal and are noted as major neurosurgical challenges due to frequent recurrence or progression. Despite standard-of-care treatment for gliomas, the prognosis of patients with higher-grade glial tumours is still poor, and hence empowering antitumour immuni...

Full description

Saved in:
Bibliographic Details
Published in:BMJ open 2023-12, Vol.13 (12), p.e072484-e072484
Main Authors: Nikoobakht, Mehdi, Shamshiripour, Parisa, Mostafavi Zadeh, Seyed Mostafa, Rahnama, Mehrana, Hajiahmadi, Fahime, Ramezani, Aghdas, Farzam Rad, Vahideh, Nazari, Elaheh, Moradi, Ali-Reza, Akbarpour, Mahzad, Ahmadvand, Davoud
Format: Article
Language:English
Subjects:
Antigens
Cells
Chemokines
Clinical trials
Cytotoxicity
Glioma
Glioma - therapy
Humans
Immune system
Immunology
Immunotherapy
Intervention
Lymphocytes
Meta-analysis
Meta-Analysis as Topic
Neurobiology
Neurological oncology
Neurology
Oncology
Review Literature as Topic
Systematic review
Systematic Reviews as Topic
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:IntroductionGlial brain tumours are highly mortal and are noted as major neurosurgical challenges due to frequent recurrence or progression. Despite standard-of-care treatment for gliomas, the prognosis of patients with higher-grade glial tumours is still poor, and hence empowering antitumour immunity against glioma is a potential future oncological prospect. This review is designed to improve our understanding of the efficacy of cell-based immunotherapies for glioma.Methods and analysisThis systematic review will be performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A comprehensive search of main electronic databases: PubMed/MEDLINE, Scopus, ISI Web of Science EMBASE and ProQuest will be done on original articles, followed by a manual review of review articles. Only records in English and only clinical trials will be encountered for full-text review. All the appropriate studies that encountered the inclusion criteria will be screened, selected and then will undergo data extraction step by two independent authors. For meta-analyses, data heterogeneity for each parameter will be first evaluated by Cochran’s Q and I2 statistics. In case of possible heterogeneity, a random-effects meta-analysis will be performed and for homogenous data, fixed-effects models will be selected for reporting the results of the proportional meta-analysis. Bias risk will be assessed through Begg’s and Egger’s tests and will also be visualised by Funnel plots.Ethics and disseminationAs this study will be a systematic review without human participants’ involvement, no ethical registration is required and meta-analysis will be presented at a peer-reviewed journal.PROSPERO registration numberCRD42022373297
ISSN:2044-6055
2044-6055
DOI:10.1136/bmjopen-2023-072484